Almond supplementation reduces serum uric acid in coronary artery disease patients: a randomized controlled trial. by Jamshed, Humaira et al.
eCommons@AKU
Department of Biological & Biomedical Sciences Medical College, Pakistan
March 2016
Almond supplementation reduces serum uric acid





Aga Khan University, anwar.gilani@aku.edu
Fateh Ali Tipoo Sultan





See next page for additional authors
Follow this and additional works at: http://ecommons.aku.edu/pakistan_fhs_mc_bbs
Part of the Cardiology Commons, Circulatory and Respiratory Physiology Commons, and the
Natural Products Chemistry and Pharmacognosy Commons
Recommended Citation
Jamshed, H., Gilani, A., Sultan, F., Amin, F., Arslan, J., Ghani, S., Masroor, M. (2016). Almond supplementation reduces serum uric
acid in coronary artery disease patients: a randomized controlled trial.. Nutrition Journal, 1-5.
Available at: http://ecommons.aku.edu/pakistan_fhs_mc_bbs/294
Authors
Humaira Jamshed, Anwar Gilani, Fateh Ali Tipoo Sultan, Faridah Amin, Jamshed Arslan Arslan, Sumaira
Ghani, and Madiha Masroor
This article is available at eCommons@AKU: http://ecommons.aku.edu/pakistan_fhs_mc_bbs/294
SHORT REPORT Open Access
Almond supplementation reduces serum
uric acid in coronary artery disease
patients: a randomized controlled trial
Humaira Jamshed1, Anwar-ul-Hassan Gilani1,2*, Fateh Ali Tipoo Sultan3, Faridah Amin1, Jamshed Arslan1,
Sumaira Ghani1 and Madiha Masroor1
Abstract
Objective: Elevated serum uric acid (UA), a biomarker of renal insufficiency, is also an independent prognostic
marker for morbidity in coronary artery disease (CAD) and poses serious health risks. This study reports the effect of
almond consumption on UA in CAD patients.
Study design: A randomized controlled clinical trial was conducted with three groups: no-intervention (NI),
Pakistani almonds (PA) or American almonds (AA). Patients were recruited from the Cardiology Clinics, Aga Khan
University Hospital. Two follow-ups were scheduled at week-6 and week-12. 150 patients were randomly divided in
three groups (50 per group). NI was not given almonds, whereas the PA and AA were given Pakistani and American
almond varieties (10 g/day), respectively; with instruction to soak overnight and eat before breakfast.
Results: Almonds supplementation significantly reduced (p < 0.05) serum UA among groups, and over time. At
week-6, UA concentrations were -13 to -16 % less in PA and AA; at week-12 the concentrations were -14 to -18 %
less, compared to NI. Systolic and diastolic blood pressure and body weights of the participants remained fairly
constant among all the groups.
Conclusion: Almonds (10 g/day), eaten before breakfast, reduces serum UA in CAD patients. Prevention of
hyperuricemia can confer protection from kidney and vascular damage and if extrapolated for general population,
dietary almonds can offer grander health benefit. Trial is registered at Australian New Zealand Clinical trial registry
as ACTRN12614000036617.
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Introduction
There has been considerable increase in global preva-
lence of hyperuricemia, in the past few years, backed by
western dietary patterns. Where higher serum uric acid
(UA) frequently indicates renal insufficiency [1], it may
also be associated with coronary artery disease (CAD)
[2], and deliberated as a prognostic marker for morbidity
and mortality, independent of other risk factors [3]. Even
in patients with no history of heart disease or stroke, ele-
vated UA was associated with higher risk of myocardial
infarction or stroke [4]. An increase in serum UA by
1 mg/dL contributes to 12 % increase in risk of CAD
death [5]. This association is believed to be stronger in
women than men [5]. But there are also some indications
where, in middle-aged men, hyperuricemia served as a risk
factor for cardiovascular and all-cause mortality [6].
UA is shown to possess anti-oxidant potential [7], which
undermines its causative role in chronic diseases. Yet, its
establishment as a comorbid risk marker is backed by re-
cent meta-analysis [8] and systemic review [5] showing
significant correlation between hyperuricemia and CAD.
Further signifying its role for cardiovascular health,
are the studies where anti-hypertensive and/or lipid-
neutralizing therapies limited UA production, thereby
reducing CAD mortality [9, 10].
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Almonds are among the nuts approved by Food and
Drug Administration – United States to have the poten-
tial of reducing CVD risk [11]. The lipid-neutralizing
properties, among others, have been extensively elabo-
rated [12]. Dietary supplementation of almonds is shown
to prevent hyperuricemia in a cardiovascular disease rat
model [13]. This study inspects the UA-reducing poten-
tial of almond supplementation in CAD patients.
Methods
Study population
Hundred and fifty CAD patients were recruited from Car-
diology Clinic at The Aga Khan University Hospital, Kara-
chi. The eligibility criteria and trial logistics have previously
been defined in detail, following the CONSORT guidelines
[14]. Briefly, patients consuming nuts on regular basis
(>15 g/d; three days/week) or those having nut allergies
were excluded. Informed consent was obtained. Using
block randomization, patients were assigned any of the fol-
lowing three groups: No Intervention (NI); Intervention
with Pakistani almonds (PA) or American almonds (AA).
Study design
Approval was obtained from Ethical Review Committee
of The Aga Khan University, Karachi, Pakistan (Applica-
tion ID: 2230-Med-ERC-12), and the trial was registered
at Australian New Zealand Clinical Trial Registry (ID:
ACTRN12614000036617).
Baseline blood was drawn and vitals (body weight,
blood pressure etc.) were recorded. Participants of NI
were instructed not to consume any nuts, specifically al-
monds, during their enrollment in trial; whereas partici-
pants of PA and AA were given almonds (10 g/day),
with the instruction to consume in a traditional way (i.e.
soak overnight, peel and eat before breakfast in the
morning). Diaries, to record almond consumption, were
provided. Compliance was monitored through regular
phone calls (twice per week). Follow-up visits were
scheduled at week-6 and week-12 (±3 days), at which
blood samples were collected and vitals were recorded.
Participants of NI received almonds after the completion
of trial.
Pakistani almonds, namely Talwar, grown in Balochistan –
Pakistan; and imported American almonds, locally available
at Utility stores in Karachi, were used. Serum concen-
tration of uric acid (UA) was measured on Roche
Cobass c-111 automated analyzer using commercially
available kit (Uric acid kit no. 4657608190).
Data were analyzed on SPSS version 17.0 and Graphpad
Prism, and results are presented as means ± SEM. Two-
way repeated measures ANOVA was used to compare
means of groups followed by Bonferroni post-tests. For
categorical data, chi-square test was used to compare dif-
ferences between groups. P-value < 0.05 was considered
statistically significant (95 % Confidence interval).
Results
The flow of participants through the trial, as per CON-
SORT format, has been reported previously [14]. Attri-
tion rate was around 15 %. The major reasons included:
failure to contact (n = 20); leaving city in summer vaca-
tions (n = 8); and a few cases of angioplasty (n = 3). The
baseline characteristics of participants in each group, is pro-
vided in Table 1. Systolic and diastolic BP and body weight
of the participants remained fairly constant (p > 0.05)
throughout the twelve weeks of the study, as seen in
Table 2.
Serum UA concentrations were similar at baseline
(Table 1), in all the groups (p > 0.05). In a male-to-male
and female-to-female comparison, the data in Table 2
show that in PA group, at week-6, males had -15 % and
females had -12 % lower UA than those in NI (p < 0.05).
Table 1 Baseline characteristics of CAD patients randomized into no-intervention, Pakistani almond or American almond groups
No Intervention1 Pakistani Almonds1 American Almonds1
Mean SEM Mean SEM Mean SEM
Age, years 61 0.2 57 1.6 61 1.5
Gender
Male, n 39 36 38
Female, n 11 14 12
Body weight, kg 73.4 0.2 79 1.9 75 1.6
Blood Pressure, mmHg
Systolic 127 0.4 126 2.4 128 2.6
Diastolic 70 0.2 67 1.2 68 1.3
Serum Uric Acid, mg/dL
Male 7.2 0.49 6.9 0.23 6.8 0.22
Female 5.9 0.34 5.7 0.14 5.6 0.21
1n = 50 per group
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At week-12, male and female participants of PA had -17
and -16 % lower concentrations, respectively, those in
NI (p < 0.05). Table 2 also shows that, at week-6, serum
UA in male and female participants of AA were -17 and
-19 % less than in NI (p < 0.05). At week-12, UA was fur-
ther reduced up to -20 and -21 % in males and females,
respectively, in AA.
Figure 1a shows comparison with respect to baseline.
At week-6, drop in serum UA concentration in male
(1 %) and female (2 %) participants of NI was insignificant
(p > 0.05). In the almonds-intervention groups, there was
a significant (p < 0.05) drop in UA; around -13 % in males
of both PA and AA, and -11 and -16 % in females of PA
and AA, respectively.
Figure 1b compares UA concentrations of baseline and
intervention. At week-12, there was negligible (-3 and -2 %)
drop in males and females of NI, while the drop in PA and
AA was significant (-16 and -14 % in males and females of
PA and -18 % in both males and females of AA; p < 0.05).
Discussion
To the best of our knowledge, this is the first almond-
intervention study on CAD patients reporting UA reduc-
tion. Previously, in rat model, dietary almonds prevented
high-fat diet-induced hyperuricemia, followed by reduced
nitric oxide (NO) production via endothelial NO synthase
(eNOS) inhibition resulting in improved vascular function
of isolated aorta [13]. So, from results in CAD patients,
we can also infer probable vascular protection.
Serum UA may be considered as a biomarker for vascu-
lar function [15]. Anticipated pathways of UA-induced
vascular dysfunction [16] include, but are not limited to:
pro-oxidative affect, whereby UA decomposes and gener-
ates free radicals; pro-inflammatory affect via association
with biomarkers like interleukins (IL-1, IL-6, IL-10, IL-18),
tumor necrosis factor (TNF-α) and C-reactive proteins
(CRP); endogenous stimulation of innate immunity; chan-
ging expression of endothelin-1; promoting angiotensin-II
production; inducing smooth muscle cell proliferation;
and direct reaction with, and depletion of NO.
Almond supplementation is shown to influence some of
these parameters. Although, Jenkins et al. report no effect
of almonds on CRP, BP or pulmonary NO [17]; Rajaram
et al. [18] observed significant reduction in CRP. Two
studies in diabetic patients [19, 20], report a drop in
CRP accompanied by anti-inflammation via IL-6
Table 2 Blood pressure and serum uric acid concentrations of CAD patients randomized into no-intervention (NI), Pakistani almonds
(PA) and American Almonds (AA) groups, at week-6 and week 12
No Intervention Pakistani Almonds American Almonds
Male Female Male Female Male Female
n = 25 n = 9 n = 27 n = 11 n = 33 n = 8
Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM
Blood Pressure
Systolic, mmHg Week 6 128 0.5 129 0.6 126 1.7 127 0.9 127 1.7 126 1.4
Week 12 126 1.2 127 0.5 124 3.1 126 1.2 125 3.4 125 0.5
Diastolic, mmHg Week 6 71 0.3 69 0.4 67 0.5 68 0.5 67 0.2 66 0.8
Week 12 70 1.8 69 1.0 66 1.2 67 1.1 67 1.0 67 0.2
Uric Acid, mg/dL Week 6 7.1 0.2 5.8 0.17 6.0* 0.22 5.1* 0.16 5.9* 0.26 4.7* 0.26
Week 12 7.0 0.3 5.8 0.25 5.8* 0.20 4.9* 0.15 5.6* 0.28 4.6* 0.27
*p <0.05 compared to respective No-Intervention control group
Fig. 1 Percentage change in serum uric acid (UA) from baseline, at
week-6 (a) and week-12 (b), in coronary artery disease patients
randomized in no-intervention (NI), Pakistani almond (PA) or American
almond (AA) groups. Values are mean ± SEM; n = 34 in NI group, n = 38
in PA group and n = 41 in AA group
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reduction; while Liu et al. [20], also reports decrease in
TNF-α by dietary almonds. Bhardwaj et al. [21], also dem-
onstrated drop in CRP, accompanied by improved flow-
mediated dilatation, indicating improved endothelial func-
tion. But more recently, Chen et al. [22] reported no effect
of almond supplementation on vascular function, CRP,
TNF-α and even the lipid profile of CAD patients in a ran-
domized cross-over clinical trial. This may be due to the
drug therapy which could mimic the effect of intervention.
Decrease in vascular cell adhesion molecules was observe,
which may indicate improvement in vascular function.
Trials longer than four to six weeks may be able to offer
detectible improvements in vascular function of CAD
patients.
Almonds are rich in L-arginine, which is a precursor of
NO. Supplementation of L-synthetic arginine reverses
hyperuricemia-induced hypertension in rats [23]. How-
ever, BP of participants in our trial remained fairly con-
stant during twelve weeks. Reason being, almost all CAD
patients were on anti-hypertensive medications, and base-
line BP was within normal ranges.
The precise underling mechanisms of almonds action
on serum uric acid remains to be explored. Certain limita-
tions of our trial include the following. The inclusion cri-
teria included only those CAD patients, who had
optimal LDL-C and sub-optimal HDL-C. This may not
truly represent the CAD population in general. Sample
size was calculated for observable improvements in
serum HDL.
Conclusion
Almond supplementation can provide holistic benefits to
CAD patients. Previous clinical studies have almonds’
potential in ameliorating dyslipidemia, the current inves-
tigation adds to its vasculo-protective effects, by present-
ing prominent reduction in serum uric acid.
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